Geron (GERN) Ending Cash Position: $64.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GERN Geron Corp GERN
25 GF Score
Price $1.48
! 4 Warning Signs
View Full Analysis

What is Geron Ending Cash Position?

Geron GERN -0.67% 25 Ending Cash Position is $64.5 Mil as of Jun. 2026. GuruFocus rates GERN with a GF Score™ of 25/100. The stock has 4 warning signs investors should review.

Geron's Ending Cash Position for the quarter that ended in Jun. 2026 was $64.5 Mil.

Geron's quarterly Ending Cash Position declined from Dec. 2025 ($79.4 Mil) to Mar. 2026 ($70.8 Mil) and declined from Mar. 2026 ($70.8 Mil) to Jun. 2026 ($64.5 Mil).

Geron's annual Ending Cash Position increased from Dec. 2023 ($71.1 Mil) to Dec. 2024 ($80.9 Mil) but then declined from Dec. 2024 ($80.9 Mil) to Dec. 2025 ($79.4 Mil).

Geron Ending Cash Position Related Terms

Geron Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Geron's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geron Ending Cash Position Chart

Geron Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.24 57.21 71.14 80.88 79.44

Geron Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.60 79.99 79.44 70.78 64.53
GERN
25GF Score
Geron Corp GERN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geron Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Geron's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=80.876+-1.436
=79.4

Geron's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=70.779+-6.248
=64.5

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $64.5 Mil mean?
Geron (GERN) has a Ending Cash Position of $64.5 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Geron and its competitors.
Is Geron's Ending Cash Position too high?
Geron's current Ending Cash Position is $64.5 Mil. Overall, Geron has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Geron's Ending Cash Position compare to ARDX and DSGN?
Geron's Ending Cash Position of $64.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Geron and its competitors. Geron's current Ending Cash Position is $64.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Geron (GERN) has a current Ending Cash Position of $64.5 Mil. The current Ending Cash Position is $64.5 Mil. Geron's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Geron (GERN), the current Ending Cash Position is $64.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
25GF Score

Get the complete analysis for GERN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.48
Price